Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases
- PMID: 27244540
- DOI: 10.1002/cncr.30085
Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases
Abstract
Background: Investigations regarding the impact of tumor biology after surgical management of colorectal liver metastasis have focused largely on overall survival. We investigated the impact of codon-specific KRAS mutations on the rates and patterns of recurrence in patients after surgery for colorectal liver metastasis (CRLM).
Methods: All patients who underwent curative-intent surgery for CRLM between 2002 and 2015 at Johns Hopkins who had available data on KRAS mutation status were identified. Clinico-pathologic data, recurrence patterns, and recurrence-free survival (RFS) were assessed using univariable and multivariable analyses.
Results: A total of 512 patients underwent resection only (83.2%) or resection plus radiofrequency ablation (16.8%). Although 5-year overall survival was 64.6%, 284 (55.5%) patients recurred with a median RFS time of 18.1 months. The liver was the initial recurrence site for 181 patients, whereas extrahepatic recurrence was observed in 162 patients. Among patients with an extrahepatic recurrence, 102 (63%) had a lung recurrence. Although overall KRAS mutation was not associated with overall RFS (P = 0.186), it was independently associated with a worse extrahepatic (P = 0.004) and lung RFS (P = 0.007). Among patients with known KRAS codon-specific mutations, patients with codon 13 KRAS mutation had a worse 5-year extrahepatic RFS (P = 0.01), whereas codon 12 mutations were not associated with extrahepatic (P = 0.11) or lung-specific recurrence rate (P = 0.24). On multivariable analysis, only codon 13 mutation independently predicted worse overall extrahepatic RFS (P = 0.004) and lung-specific RFS (P = 0.023).
Conclusions: Among patients undergoing resection of CRLM, overall KRAS mutation was not associated with RFS. KRAS codon 13 mutations, but not codon 12 mutations, were associated with a higher risk for overall extrahepatic recurrence and lung-specific recurrence. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2698-2707. © 2016 American Cancer Society.
Keywords: KRAS mutation; codon-specific mutation; colorectal liver metastasis; hepatectomy; recurrence patterns.
© 2016 American Cancer Society.
Similar articles
-
Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.JAMA Surg. 2015 Aug;150(8):722-9. doi: 10.1001/jamasurg.2015.0313. JAMA Surg. 2015. PMID: 26038887 Free PMC article.
-
Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.Ann Surg Oncol. 2015 Dec;22(13):4158-65. doi: 10.1245/s10434-015-4587-z. Epub 2015 Jun 16. Ann Surg Oncol. 2015. PMID: 26077912
-
KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.Ann Surg Oncol. 2016 Jun;23(6):1890-6. doi: 10.1245/s10434-016-5087-5. Epub 2016 Jan 19. Ann Surg Oncol. 2016. PMID: 26786089
-
From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.Surg Oncol. 2016 Sep;25(3):332-8. doi: 10.1016/j.suronc.2016.07.002. Epub 2016 Jul 14. Surg Oncol. 2016. PMID: 27566041
-
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8. Surg Oncol. 2018. PMID: 29937183
Cited by
-
Gene Alterations, Mediators, and Artificial Intelligence in Colorectal Liver Metastases.Cells. 2022 Jul 15;11(14):2205. doi: 10.3390/cells11142205. Cells. 2022. PMID: 35883648 Free PMC article.
-
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone provokes progression from chronic pancreatitis to pancreatic intraepithelial neoplasia.iScience. 2021 Dec 18;25(1):103647. doi: 10.1016/j.isci.2021.103647. eCollection 2022 Jan 21. iScience. 2021. PMID: 35028532 Free PMC article.
-
Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases.Cancers (Basel). 2022 Feb 5;14(3):816. doi: 10.3390/cancers14030816. Cancers (Basel). 2022. PMID: 35159083 Free PMC article. Review.
-
Prognostic Models Incorporating RAS Mutation to Predict Survival in Patients with Colorectal Liver Metastases: A Narrative Review.Cancers (Basel). 2022 Jun 30;14(13):3223. doi: 10.3390/cancers14133223. Cancers (Basel). 2022. PMID: 35804994 Free PMC article. Review.
-
Prognostic Value of KRAS Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients.J Cancer. 2021 Jul 3;12(17):5331-5337. doi: 10.7150/jca.59193. eCollection 2021. J Cancer. 2021. PMID: 34335949 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous